AbbVie Inc. (ABBV) vs Berkshire Hathaway Inc. (BRK-B)

AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.

Berkshire Hathaway Inc. is a publicly traded diversified holding company with major businesses and investments across insurance, freight rail, energy, manufacturing, retail, and financial assets. Its shares give investors exposure to the operating performance of its subsidiaries as well as the value of its large public-equity portfolio. The company's performance is influenced by insurance underwriting results, investment returns, economic activity, interest rates, capital allocation, and broader market conditions.